Latest Tarceva Stories

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva(R)) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin(R)) in models of breast cancer. These preclinical results were published in the July issue of the...

* Alocrest(tm) Phase 1 Data Demonstrates Potential for Improved Safety and Efficacy Compared to Conventional Vinorelbine * Menadione Topical Lotion Restores Kinase Activity and Does Not Inhibit the Anti-Tumor Effect of Erlotinib (Tarceva(r)) in Preclinical Models SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the company's...

LOS ANGELES (Reuters) - A mid-stage trial suggests that a combination of cancer drugs Avastin and Tarceva can prolong survival in patients with advanced lung cancer, compared with chemotherapy alone, drug makers Genentech Inc. and OSI Pharmaceuticals said on Monday Avastin, made by Genentech, is the first cancer drug designed to work by cutting off blood supply to tumors. Tarceva, a product of Genentech and OSI, is an oral drug designed to target the human epidermal growth factor...

By Ransdell PiersonNEW YORK -- A Pfizer Inc. kidney cancer drug has also shown promise in a small mid-stage trial as a treatment for the most common form of lung cancer, researchers said on Saturday.The new study involved 63 patients whose non-small cell lung cancer had progressed despite earlier treatments with standard chemotherapy. All patients were then given Pfizer's once-daily pill, Sutent, as a stand-alone treatment and continued to take it until their disease progressed.Tumors shrank...

WASHINGTON (Reuters) - Adding a prescription arthritis drug to a targeted cancer therapy triples the number of lung cancer patients who are helped, U.S. researchers said on Thursday. Pfizer's anti-inflammatory drug Celebrex, given along with OSI Pharmaceuticals Inc.'s Tarceva, increased response rates in lung cancer patients from about 10 percent to 33 percent, reported the researchers at the University of California, Los Angeles. The study, published in the journal Clinical Cancer...

CHICAGO (Reuters) - Genentech Inc. said on Tuesday early results from a mid-stage trial show that combining lung cancer drug Tarceva with Avastin works no better than Avastin alone in patients with advanced kidney cancer, sending shares of Tarceva partner OSI Pharmaceuticals Inc. down 7 percent. As a result, the world's No. 2 biotechnology company said it will not pursue further studies of the Avastin/Tarceva combination in kidney cancer but will continue to analyze the results of the...